Literature DB >> 1870215

Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production.

J Park1, C D Morrow.   

Abstract

The expression of the gag-pol polyprotein of human immunodeficiency virus type 1 (HIV-1) occurs via ribosomal frameshifting between the gag and pol genes. Because low levels of the gag-pol precursor are naturally produced in HIV-1-infected cells, a limited amount of information is available on the biology of this molecule. To further study this polyprotein, two mutant HIV-1 proviral genomes were created to position the gag and pol genes in the same translational reading frame. The mutations inserted a single thymidine nucleotide at the site of ribosomal frameshifting (nucleotide 1635), which results in the addition of a phenylalanine residue (frameshift 1 [FS1]), or a single adenine nucleotide, which results in the addition of a leucine residue (frameshift 2 [FS2]). Transfection of the mutant proviral genomes into COS-1 cells resulted in the expression of the p160gag-pol polyprotein precursor as well as the proteolytically processed gag and pol gene products. Metabolic labeling of the transfected cells with [3H]myristic acid revealed that the p160gag-pol and p17gag proteins expressed from the mutant genomes were myristylated. While the supernatants from COS-1 cells transfected with wild-type or mutant proviral genomes contained similar amounts of p24 antigen, the levels of reverse transcriptase were, on the average, 10 times greater in the supernatants from cells transfected with the FS1 and FS2 proviral genomes. The cells transfected with the wild-type proviral genome released infectious viral particles, while the mutant proviral genomes released p24 and reverse transcriptase in the absence of detectable particle formation. The mutant proviral genomes were completely noninfectious as determined by coculture of the transfected COS-1 cells with SupT1 cells. These results demonstrate that the gag-pol polyprotein of HIV-1 contains the appropriate signals for proteolytic processing and association with intracytoplasmic membranes in the absence of virion formation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1870215      PMCID: PMC248980     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events.

Authors:  A M Schultz; A Rein
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

2.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1.

Authors:  M A Navia; P M Fitzgerald; B M McKeever; C T Leu; J C Heimbach; W K Herber; I S Sigal; P L Darke; J P Springer
Journal:  Nature       Date:  1989-02-16       Impact factor: 49.962

3.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.

Authors:  H G Göttlinger; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

4.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

5.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

6.  Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli.

Authors:  H G Kräusslich; H Schneider; G Zybarth; C A Carter; E Wimmer
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Active human immunodeficiency virus protease is required for viral infectivity.

Authors:  N E Kohl; E A Emini; W A Schleif; L J Davis; J C Heimbach; R A Dixon; E M Scolnick; I S Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease.

Authors:  T D Meek; B D Dayton; B W Metcalf; G B Dreyer; J E Strickler; J G Gorniak; M Rosenberg; M L Moore; V W Magaard; C Debouck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

10.  X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes.

Authors:  R Lapatto; T Blundell; A Hemmings; J Overington; A Wilderspin; S Wood; J R Merson; P J Whittle; D E Danley; K F Geoghegan
Journal:  Nature       Date:  1989-11-16       Impact factor: 49.962

View more
  91 in total

1.  Translational recoding signals between gag and pol in diverse LTR retrotransposons.

Authors:  Xiang Gao; Ericka R Havecker; Pavel V Baranov; John F Atkins; Daniel F Voytas
Journal:  RNA       Date:  2003-12       Impact factor: 4.942

2.  Solution structure of the HIV-1 frameshift inducing stem-loop RNA.

Authors:  David W Staple; Samuel E Butcher
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

3.  Transposition of a Ty3 GAG3-POL3 fusion mutant is limited by availability of capsid protein.

Authors:  J Kirchner; S B Sandmeyer; D B Forrest
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

4.  Efficiency of a programmed -1 ribosomal frameshift in the different subtypes of the human immunodeficiency virus type 1 group M.

Authors:  Martin Baril; Dominic Dulude; Karine Gendron; Guy Lemay; Léa Brakier-Gingras
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

5.  Complementation studies with Rous sarcoma virus gag and gag-pol polyprotein mutants.

Authors:  S Oertle; N Bowles; P F Spahr
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

6.  Foamy virus Pol protein expressed as a Gag-Pol fusion retains enzymatic activities, allowing for infectious virus production.

Authors:  Eun-Gyung Lee; Amber Sinicrope; Dana L Jackson; Shuyuarn F Yu; Maxine L Linial
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

7.  Strategies for recognition of stem-loop RNA structures by synthetic ligands: application to the HIV-1 frameshift stimulatory sequence.

Authors:  Prakash B Palde; Leslie O Ofori; Peter C Gareiss; Jaclyn Lerea; Benjamin L Miller
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

8.  Identification of a cellular factor that modulates HIV-1 programmed ribosomal frameshifting.

Authors:  Yoshifumi Kobayashi; Jianling Zhuang; Stuart Peltz; Joseph Dougherty
Journal:  J Biol Chem       Date:  2010-04-23       Impact factor: 5.157

9.  Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.

Authors:  Lucile Larrouy; C Chazallon; R Landman; C Capitant; G Peytavin; G Collin; C Charpentier; A Storto; G Pialoux; C Katlama; P M Girard; P Yeni; J P Aboulker; F Brun-Vezinet; D Descamps
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

10.  Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins.

Authors:  Ewan P Plant; Rasa Rakauskaite; Deborah R Taylor; Jonathan D Dinman
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.